Heart patients in England and Wales offered more treatment choice
Revised guidance from the National Institute for Health and Care Excellence, recommends once-daily, oral antiplatelet prasugrel (Efient®), in combination with aspirin, as a cost-effective option compared with generic clopidogrel, for a wider group of acute coronary syndrome patients having primary or delayed percutaneous coronary intervention.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: AMcculloch Tags: *** Editor's Pick Cardiovascular medicine acs acute coronary syndrome aspirin clopidogrel Efient® Latest News National Institute for Health and Care Excellence pci percutaneous coronary intervention prasugrel Source Type: news
More News: Angioplasty | Aspirin | Cardiology | Cardiovascular | Clopidogrel | Coronary Angioplasty | Drugs & Pharmacology | Health | Heart | Percutaneous Coronary Intervention | Plavix